Intervention

NIFEdipine ER

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting1

Common conditions7

Lead sponsors shown5

Clinical trials

5 shown

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled TrialNCT05309460 · 2022-06-20

RECRUITING

Effect of a Proposed Cav1.3 Inhibitor in Primary AldosteronismNCT05686993 · 2023-04-24

COMPLETED

Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum HypertensionNCT05049616 · 2021-10-18

COMPLETED

Amlodipine Versus Nifedipine ER for the Management of Postpartum HypertensionNCT04790279 · 2021-04-09

COMPLETED

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum PeriodNCT04236258 · 2020-01-24

COMPLETED

Common conditions

Hypertension in Pregnancy4 Postpartum Preeclampsia3 Endocrine Hypertension1 Gestational Hypertension1 Postpartum1 Preeclampsia Severe1 Primary Aldosteronism1

Leading sponsors

Brigham and Women's Hospital 1 Nebraska Methodist Health System 1 Prisma Health-Upstate 1 Queen Mary University of London 1 The University of Texas Health Science Center, Houston 1

Trial status mix

COMPLETED4

RECRUITING1

Phase mix

PHASE44

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.